{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:19:36Z","timestamp":1761506376263,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.cllc.2021.03.011","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T03:59:37Z","timestamp":1616817577000},"page":"441-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Three Decades of Malignant Pleural Mesothelioma: An Academic Center Experience"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-2861","authenticated-orcid":false,"given":"Abdullah","family":"Nasser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Baird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu D.","family":"Saint-Pierre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayvan","family":"Amjadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Laurie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Wheatley-Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2021.03.011_bib0001","doi-asserted-by":"crossref","unstructured":"Saint-Pierre MD, Pease C, Mithoowani H, et\u00a0al. Malignant pleural mesothelioma outcomes in the era of combined platinum and folate antimetabolite chemotherapy. Lung Cancer Int2015; 2015:590148.","DOI":"10.1155\/2015\/590148"},{"key":"10.1016\/j.cllc.2021.03.011_bib0002","doi-asserted-by":"crossref","unstructured":"Domen A, Berzenji L, Hendriks JM, et\u00a0al. Extrapleural pneumonectomy: still indicated?Transl Lung Cancer Res2018; 7:550-5.","DOI":"10.21037\/tlcr.2018.07.07"},{"key":"10.1016\/j.cllc.2021.03.011_bib0003","doi-asserted-by":"crossref","unstructured":"Treasure T, Lang-Lazdunsk L, Waller D, et\u00a0al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol2011; 12:763-72","DOI":"10.1016\/S1470-2045(11)70149-8"},{"key":"10.1016\/j.cllc.2021.03.011_bib0004","doi-asserted-by":"crossref","unstructured":"Azzouqa A-G, Stevenson JP. The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma. Onco Targets Ther2016; 9:7247-52.","DOI":"10.2147\/OTT.S100214"},{"key":"10.1016\/j.cllc.2021.03.011_bib0005","doi-asserted-by":"crossref","unstructured":"Van Schil PE, Opitz I, Weder W, et\u00a0al. Multimodal management of malignant pleural mesothelioma: where are we today?Eur Respir J2014; 44:754-64.","DOI":"10.1183\/09031936.00207213"},{"key":"10.1016\/j.cllc.2021.03.011_bib0006","doi-asserted-by":"crossref","unstructured":"Vogelzang N, Rusthoven JJ, Symanowski J, et\u00a0al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol2003; 21:2636-44.","DOI":"10.1200\/JCO.2003.11.136"},{"key":"10.1016\/j.cllc.2021.03.011_bib0007","doi-asserted-by":"crossref","unstructured":"Vogelzang N, Symanowski J, Rusthoven J, et\u00a0al. Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs. cisplatin in patients with malignant pleural mesothelioma (MPM). Lung Cancer2005; 49:S230.","DOI":"10.1016\/S0169-5002(05)80928-6"},{"key":"10.1016\/j.cllc.2021.03.011_bib0008","doi-asserted-by":"crossref","unstructured":"Van Meerbeeck JP, Manegold C, Gaafar R, et\u00a0al. A randomized phase III study of cisplatine with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the EORTC Lung Cancer Group and NCIC. J Clin Oncol2005; 23:6881-9","DOI":"10.1200\/JCO.20005.14.589"},{"key":"10.1016\/j.cllc.2021.03.011_bib0009","doi-asserted-by":"crossref","unstructured":"van den Toorn LM, Schaap E, Surmont VF, Pouw EM, van der Rijt KC, van Klaveren RJ. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter. Lung Cancer2005; 50:123-7.","DOI":"10.1016\/j.lungcan.2005.05.016"},{"key":"10.1016\/j.cllc.2021.03.011_bib0010","doi-asserted-by":"crossref","unstructured":"Bottomley A, Coens C, Efficace F, et\u00a0al. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol2007; 25:5770-6.","DOI":"10.1200\/JCO.2007.12.5294"},{"key":"10.1016\/j.cllc.2021.03.011_bib0011","doi-asserted-by":"crossref","unstructured":"Herndon JE, Green MR, Chahinian P, et\u00a0al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest1998: 113:732-31.","DOI":"10.1378\/chest.113.3.723"},{"key":"10.1016\/j.cllc.2021.03.011_bib0012","doi-asserted-by":"crossref","unstructured":"Frick AE, Nackaerts K, Moons J, et\u00a0al. Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy. Eur J Cardiothorac Surg2019; 55:934-41.","DOI":"10.1093\/ejcts\/ezy385"},{"key":"10.1016\/j.cllc.2021.03.011_bib0013","doi-asserted-by":"crossref","unstructured":"Ost DE, Jimenez CA, Lei X, et\u00a0al. Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters. Chest2014; 145:1347-56.","DOI":"10.1378\/chest.13-1908"},{"key":"10.1016\/j.cllc.2021.03.011_bib0014","doi-asserted-by":"crossref","unstructured":"Boshuizen RC, Vd Noort V, Burgers JA, et\u00a0al. A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14). Lung Cancer2017; 108:9-14.","DOI":"10.1016\/j.lungcan.2017.01.019"},{"key":"10.1016\/j.cllc.2021.03.011_bib0015","doi-asserted-by":"crossref","unstructured":"Zalcman, G, Mazieres J, Margery J, et\u00a0al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet2016; 387:1405-14.","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"10.1016\/j.cllc.2021.03.011_bib0016","doi-asserted-by":"crossref","unstructured":"Zalcman G, Peters S, Mansfield AS, et\u00a0al. CheckMate 743: a phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma. J Clin Oncol2017; 35:TPS8581.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8581"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730421000656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730421000656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:12:46Z","timestamp":1761505966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730421000656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1525730421000656"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2021.03.011","relation":{},"ISSN":["1525-7304"],"issn-type":[{"type":"print","value":"1525-7304"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three Decades of Malignant Pleural Mesothelioma: An Academic Center Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2021.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}